What is enGene Therapeutics Inc. 's market cap?

enGene Therapeutics Inc. (ENGN) has a market capitalization of $117.9M and trades on NASDAQ.

Who are enGene Therapeutics Inc. 's competitors?

enGene Therapeutics Inc. 's key competitors include Merck & Co., ImmunityBio Inc., Johnson & Johnson Inc., and others. These companies compete in similar markets and product categories.

Who does enGene Therapeutics Inc. partner with?

enGene Therapeutics Inc. 's notable partners include Nature Technology Corporation, Aldevron, LLC.

What subsidiaries does enGene Therapeutics Inc. have?

enGene Therapeutics Inc. 's subsidiaries include enGene Inc..

Where is enGene Therapeutics Inc. headquartered?

enGene Therapeutics Inc. is headquartered in Canada and employs approximately 33 people. It has been publicly traded since 2023.

enGene Therapeutics Inc.

ENGN

enGene Therapeutics is a clinical-stage biotechnology company focused on mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs.

Market cap

$117.9M-34.1%

Table of contents

Earnings

Q2 2026 report

June 15, 2026

EPS-$0.43Beat by $0.05

Read the full report

Next report

Sep 14, 2026 (in a month)

EPS estimate-$0.47

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Merck & Co.$322.95B+53.0%

ImmunityBio, Inc.$7.3B+213%

CG Oncology$6.5B+229%

UroGen Pharma$2.0B+131%

Aura Biosciences, Inc.$740.6M+70.9%

Protara Therapeutics, Inc.$227.1M+75.7%

enGene Therapeutics Inc. $117.9M-36.6%

By revenue growth

CG Oncology+666%

ImmunityBio, Inc.+352%

UroGen Pharma+52.9%

Johnson & Johnson+8.1%

Merck & Co.+2.9%

By net margin

Johnson & Johnson21.48%-3.5pp

Merck & Co.13.59%-13.7pp

UroGen Pharma-94.83%+55.8pp

ImmunityBio, Inc.-606.15%+704pp

CG Oncology-3,682.61%+12,263pp

Profile

enGene Therapeutics is a clinical-stage biotechnology company focused on mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The company utilizes its proprietary dually derived chitosan (DDX) gene delivery platform to develop non-viral genetic medicines for diseases with high clinical needs. Its primary focus is on treating non-muscle invasive bladder cancer (NMIBC) by promoting a pro-inflammatory, anti-tumor microenvironment.

Competitive position

A clinical-stage innovator in non-viral gene delivery with a lead product candidate holding FDA Fast Track and RMAT designations for BCG-unresponsive NMIBC.

GeographiesUnited States, Canada

Customer segmentsHealthcare Providers, Pharmaceutical Companies

Business modelBiotechnology R&D, Intellectual Property Licensing

SuppliersContract Manufacturing Organizations (CMOs), Plasmid DNA suppliers, Specialized chemical suppliers (PEG-b-PLE), Clinical Research Organizations (CROs)

CustomersCommunity urology centers, Academic medical centers, International pharmaceutical partners

CountryCanada

Listed2023

Employees33.0

CEORonald H. W. Cooper

SectorHealthcare

IndustryBiotechnology

Websiteengene.com

FilingsSEC EDGAR

Questions, answered.

What is enGene Therapeutics Inc. 's market cap?: enGene Therapeutics Inc. (ENGN) has a market capitalization of $117.9M and trades on NASDAQ.
Who are enGene Therapeutics Inc. 's competitors?: enGene Therapeutics Inc. 's key competitors include Merck & Co., ImmunityBio Inc., Johnson & Johnson Inc., and others. These companies compete in similar markets and product categories.
Who does enGene Therapeutics Inc. partner with?: enGene Therapeutics Inc. 's notable partners include Nature Technology Corporation, Aldevron, LLC.
What subsidiaries does enGene Therapeutics Inc. have?: enGene Therapeutics Inc. 's subsidiaries include enGene Inc..
Where is enGene Therapeutics Inc. headquartered?: enGene Therapeutics Inc. is headquartered in Canada and employs approximately 33 people. It has been publicly traded since 2023.